Patents Assigned to LEO Laboratories Limited
-
Patent number: 10143638Abstract: The present invention relates generally to the cosmetic treatment of aged skin. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating photo-aged and/or chronologically-aged skin.Type: GrantFiled: February 12, 2010Date of Patent: December 4, 2018Assignee: LEO Laboratories LimitedInventors: Steven Martin Ogbourne, David Thomas, Ryan Moseley, James Harrison Aylward
-
Patent number: 9895334Abstract: The present invention relates generally to the treatment of cutaneous lesions containing cells infected by a virus, as well as compositions for the treatment of such lesions. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating lesions caused by infection with a papilloma virus, such as a mammalian papilloma virus, in particular a Human Papilloma Virus.Type: GrantFiled: April 30, 2008Date of Patent: February 20, 2018Assignee: LEO Laboratories LimitedInventors: Steven Martin Ogbourne, Andreas Suhrbier, James Harrison Aylward
-
Patent number: 9861603Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.Type: GrantFiled: May 24, 2016Date of Patent: January 9, 2018Assignee: LEO Laboratories LimitedInventors: Marc Barry Brown, Michael Edward Donald Crothers, Tahir Nazir
-
Patent number: 9833428Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.Type: GrantFiled: May 2, 2014Date of Patent: December 5, 2017Assignee: LEO Laboratories LimitedInventors: Marc Barry Brown, Michael Crothers, Tahir Nazir
-
Patent number: 9833429Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.Type: GrantFiled: May 24, 2016Date of Patent: December 5, 2017Assignee: LEO Laboratories LimitedInventors: Marc Barry Brown, Michael Edward Donald Crothers, Tahir Nazir
-
Patent number: 9820959Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.Type: GrantFiled: May 24, 2016Date of Patent: November 21, 2017Assignee: LEO Laboratories LimitedInventors: Marc Barry Brown, Michael Edward Donald Crothers, Tahir Nazir
-
Patent number: 9789078Abstract: The present invention relates to cyclic or repeated use of the ingenol mebutate for topical treatment of actinic keratosis lesions. Generally speaking, the present invention comprises a first ingenol mebutate treatment cycle and a second ingenol mebutate treatment cycle, wherein the first treatment cycle topically treats a treatment area with a topical gel formulated with ingenol mebutate at a selected dosage strength for a specified treatment regimen, and the second ingenol mebutate treatment cycle comprises topically re-treating the treatment area with the same topical ingenol mebutate gel for the same specified treatment regimen, if following the first treatment cycle, the treatment area failed to clear or failed to remain clear of AK lesions. The present invention further relates to spot or individual lesion therapy in the treatment area following the topical bi-cyclic therapy with ingenol mebutate.Type: GrantFiled: May 15, 2013Date of Patent: October 17, 2017Assignee: LEO Laboratories LimitedInventor: Kirsten Norrelund
-
Publication number: 20170217910Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: ApplicationFiled: April 14, 2017Publication date: August 3, 2017Applicant: LEO LABORATORIES LIMITEDInventors: Gunnar GRUE-SØRENSEN, Xifu LIANG, Thomas HÖGBERG, Kristoffer MÅNSSON, Per VEDSØ, Thomas VIFIAN
-
Patent number: 9713608Abstract: The invention relates to the treatment of actinic keratosis on the trunk (except chest) or Extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate).Type: GrantFiled: October 27, 2014Date of Patent: July 25, 2017Assignee: LEO Laboratories LimitedInventors: Johan Selmer, Kim Mark Knudsen
-
Patent number: 9708286Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: GrantFiled: June 24, 2015Date of Patent: July 18, 2017Assignee: LEO LABORATORIES LIMITEDInventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø, Thomas Vifian
-
Patent number: 9676698Abstract: The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.Type: GrantFiled: June 9, 2016Date of Patent: June 13, 2017Assignee: LEO Laboratories LimitedInventors: Thomas Hogberg, Gunnar Grue-Sorensen, Xifu Liang, Anne Marie Horneman, Anders Klarskov Petersen
-
Patent number: 9656945Abstract: The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: GrantFiled: December 22, 2011Date of Patent: May 23, 2017Assignee: LEO LABORATORIES LIMITEDInventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø
-
Patent number: 9624157Abstract: The present invention provides a method for preparing ingenol-3-angelate.Type: GrantFiled: July 11, 2013Date of Patent: April 18, 2017Assignee: LEO Laboratories LimitedInventor: Xifu Liang
-
Patent number: 9603822Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.Type: GrantFiled: May 24, 2016Date of Patent: March 28, 2017Assignee: LEO Laboratories LimitedInventors: Marc Barry Brown, Michael Edward Donald Crothers, Tahir Nazir
-
Patent number: 9526714Abstract: The invention provides novel methods for topical treatment of skin lesions such as actinic keratosis over treatment areas up to 250 cm2.Type: GrantFiled: March 24, 2014Date of Patent: December 27, 2016Assignee: LEO Laboratories LimitedInventors: Torsten Skov, Anita Melgaard
-
Patent number: 9440906Abstract: The present invention relates to a novel crystalline form of ingenol mebutate, methods of preparation thereof, and to its use. More specifically, the invention relates to the conversion of amorphous ingenol mebutate (ingenol-3-angelate, PEP005) to a crystalline form, which was characterized by single crystal X-Ray crystallography (XRC), attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy and Differential Scanning calorimetry (DSC).Type: GrantFiled: February 17, 2014Date of Patent: September 13, 2016Assignee: LEO Laboratories LimitedInventor: Steven Martin Ogbourne
-
Patent number: 9422309Abstract: The present invention relates to a compound according to formula (I) wherein R1 represents optionally substituted heteroaryl, and pharmaceutically acceptable salts, hydrates, solvates or pharmaceutically acceptable and physiologically cleavable esters thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. diseases associated with hyperplasia, neoplasia or dysplasia, with said compounds, to methods of treatment of cosmetic indications with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: GrantFiled: June 21, 2013Date of Patent: August 23, 2016Assignee: LEO LABORATORIES LIMITEDInventors: Xifu Liang, Thomas Högberg, Bjarne Nørremark, Kristoffer Månsson, Carsten Ryttersgaard, Gunnar Grue-Sørensen
-
Patent number: 9416084Abstract: The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.Type: GrantFiled: December 1, 2014Date of Patent: August 16, 2016Assignee: LEO Laboratories LimitedInventors: Thomas Hogberg, Gunnar Grue-Sorensen, Xifu Liang, Anne Marie Horneman, Anders Klarskov Petersen
-
Patent number: 9409931Abstract: The present invention relates to a compound according to formula I wherein R1 represents hydrogen, R2 represents hydroxyl and R3 represents hydroxyl; or R1 represents methyl, R2 represents hydroxyl and R3 represents hydrogen; or R1 represents methyl, R2 represents hydrogen and R3 represents hydroxyl; or R1 represents methyl, R2 represents hydrogen and R3 represents hydrogen; or pharmaceutically acceptable hydrates or solvates thereof. The invention further relates to said compounds for use as a medicament, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds and to intermediates for the preparation of said compounds.Type: GrantFiled: June 15, 2015Date of Patent: August 9, 2016Assignee: LEO LABORATORIES LIMITEDInventors: Phillippe S. Baran, Jakob Felding, Yehua Jin, Chien-Hung Yeh
-
Patent number: 9402823Abstract: The invention provides ingenol compounds for treating seborrheic keratosis.Type: GrantFiled: December 16, 2011Date of Patent: August 2, 2016Assignee: LEO Laboratories LimitedInventors: John Zibert, Kresten Skak, Inge Boe